C5 and neoplasm: PTX3 is described as an oncosuppressor in mouse models, inhibiting complement activation via FH recruitment, limiting the production of C5a and CCL2 (a pro-inflammatory chemokine) and avoiding the recruitment of tumor-promoting macrophages.